



# Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has an editorial commentary:  
<https://doi.org/10.1183/13993003.00149-2022>

Received: 29 July 2021  
Accepted: 30 Aug 2021

## To the Editor:

In Bangladesh, a standardised short treatment regimen (STR) was highly effective in patients diagnosed with rifampicin-resistant tuberculosis (RR-TB), without proof of initial resistance to fluoroquinolone, and no prior treatment for RR-TB [1]. The STR relied on a fluoroquinolone, either gatifloxacin, levofloxacin or moxifloxacin, as core drug, with gatifloxacin being most effective in assuring relapse-free cure [2]. A second-line injectable was used during at least the first four months to prevent the selection of fluoroquinolone-resistant (sub)populations [3]. Other drugs served as companion drugs.

Up to now, there is little evidence on effective standardised short treatment for fluoroquinolone-resistant RR-TB [4]. Before bedaquiline was available in Bangladesh, in patients with initial resistance to fluoroquinolone but susceptibility to kanamycin on rapid local phenotypic drug susceptibility testing (DST) [5], both linezolid (L) and high-dose gatifloxacin (G) were added to the same background regimen (components: K, kanamycin; Pt, prothionamide; Hh, high-dose isoniazid; C, clofazimine; E, ethambutol; and Z, pyrazinamide) to constitute a linezolid-strengthened STR (LZD/GFX-STR: 2LGKPtHhCEZ/2GKPtHhCEZ/ 5GCEZ). Once bedaquiline (B) became available, it was added to the background regimen to constitute a bedaquiline-based STR (BDQ-STR: 4BKPtHhCEZ/ 5BCEZ). In the first regimen, gatifloxacin was still included. High-dose fluoroquinolones can overcome fluoroquinolone resistance when the level of resistance is not high [6]. Linezolid (600 mg), since recently categorized as a “group A” by the World Health Organization, was added to increase the bactericidal and sterilising activity of the regimen [7]. In the second regimen, bedaquiline, a drug with high bactericidal and high sterilising activity, replaced the fluoroquinolone as core drug and was used throughout treatment [8]. All RR-TB patients started on either LZD/GFX-STR or BDQ-STR were studied. *A posteriori* reference DST for second-line drugs was done either in Bangladesh or at the Supranational Reference Laboratory in Antwerp. Initial fluoroquinolone resistance was categorised as “high-level” if the minimum inhibitory concentration (MIC) for GFX was  $2 \text{ mg}\cdot\text{L}^{-1}$  or higher on Löwenstein–Jensen, or ofloxacin  $8 \text{ mg}\cdot\text{L}^{-1}$  on agar. Mutation analysis was performed using whole-genome or Sanger sequencing. Methods used are described elsewhere [9]. All patients starting any STR regimen provided written informed consent. Ethics approval for the present deidentified analysis was provided by the Institute of Tropical Medicine institutional review board (1233/88).

Table 1 shows all 21 patients treated with either an LZD/GFX-STR or BDQ-STR. Two patients with fluoroquinolone-susceptible RR-TB and treated for the first time with a second-line gatifloxacin-based regimen (LZD/GFX-STR) were excluded. In both, the effect of strengthening the STR with LZD could not be assessed as gatifloxacin was still a fully active core drug and drove relapse-free cure. One patient treated with the BDQ-STR had fluoroquinolone-susceptible RR-TB. Here the presence or absence of initial resistance to fluoroquinolone did not affect the treatment outcome, as no fluoroquinolone was included in the BDQ-STR. This patient was not excluded from further analysis. Another patient was excluded because the bacteriological effect of BDQ-STR could not be assessed. After a good initial response with culture conversion at month 1, this patient became extremely non-adherent, culture reverted at month 4 and he refused further treatment after 6 months. The remaining 18 patients were included in the analysis of the bacteriological effect of either strengthening a gatifloxacin-based STR with linezolid or replacing the fluoroquinolone with bedaquiline.



Shareable abstract (@ERSpublications)

**In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect.** <https://bit.ly/3gWuf9z>

**Cite this article as:** Decroo T, Aung KJM, Hossain MA, *et al.* Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis. *Eur Respir J* 2022; 59: 2102124 [DOI: 10.1183/13993003.02124-2021].



TABLE 1 Characteristics and outcomes of patients treated with a bedaquiline-based or linezolid-strengthened shorter rifampicin-resistant tuberculosis treatment regimen

Cohort/patient	Baseline BMI, kg·m <sup>-2</sup> (weight, kg)	Baseline SSM AR; FDA	Previous unsuccessful SL regimen	Previous SL outcome	FQ pDST (gDST)	K pDST	Pt pDST	Culture follow-up <sup>¶</sup>	Conversion	Outcome
<b>BDQ-STR</b> n or median (IQR)	17.8 (15.0–18.8)		Yes: 5 No: 6	FL: 4 RL: 1 NA: 6	R: 10 S: 1	S: 11	R: 1 S: 7 U: 3	Stable conversion: M1: 7 M2: 2 (including 1 death) M6: 1 None: 1 (1 RL)		RL-free cure: 9 RL: 1 Died: 1
A	18.8 (50)	3+; 2+	No <sup>#</sup>	NA	R GFXMIC 4 (94Gly)	S	S	N/NNNN_N_NN/NNNN <sup>##</sup>	M1	RL-free cure
B	16.7 (35)	3+; 2+	Yes (GFX-STR)	FL	R GFXMIC 8 (94Gly)	S	S	N/NNN_NN___/##	M1	RL-free cure
C	21.6 (46)	3+; 1+	Yes (GFX-STR) <sup>#</sup>	FL	R GFXMIC 2 (94Tyr)	S	S	P/NNNNNN_NN/NNN	M1	RL-free cure
D	18.2 (52)	3+; 2+	Yes (LFX-STR)	FL	R GFXMIC 2 (94Tyr)	S	S	P/NPPP_N_NN/NNNN	M6	RL-free cure
E	15.4 (40)	2+; 2+	No	NA	R GFXMIC >2	S	U	P/PNNNN_N_N_N/NNNN	M2	RL-free cure
F	19.0 (48)	1+; Sc	No	NA	S	S	U	P/NNNN_N_NN/N	M1	RL-free cure
H	18.6 (50)	3+; 2+	Yes (OFX-reg)	RL	R GFXMIC >2	S	S	P/NNNN_N_NN/NNNN	M1	RL-free cure
I	15.0 (36)	3+; 3+	No	NA	R GFXMIC >2	S	U	P/NNNN_N_NN/N	M1	RL-free cure
J	17.8 (38)	3+; 2+	No <sup>#</sup>	NA	R GFXMIC >2	S	R	P/NNNN_N_NN/NNNN	M1	RL-free cure
K	12.2 (32)	3+; 2+	Yes (LFX-STR)	FL	R GFXMIC >2	S	S	P/PPNNNN_NN/P	M3/RL	Relapse <sup>f</sup>
L	12.8 (30)	2+; 1+	No	NA	R GFXMIC >2	S	U	P/___ <sup>¶¶</sup>	M2 <sup>¶¶</sup>	Died
M	17.8 (38)	2+; 1+	No <sup>#</sup>	NA	R GFXMIC >2	S	R	P/NNNP	M1/STOP	STOP/LTFU
<b>LZD/GFX-STR</b> n or median (IQR)	16.9 (15.2–19.6)		Yes: 0 No: 7	NA:7	R:7	S: 7	R: 1 S: 7	M2: 2 M3: 1 None: 4 (3 FL, 1 died)		RL-free cure: 3 FL: 3 Died: 1
p-value <sup>†</sup>	0.8 (0.7)	1.0; 0.7	0.04	NA	1.0	1.0	0.9	0.01		0.09 <sup>§</sup>
N	16.9 (46)	2+; 1+	No	NA	R GFXMIC 4 (94Gly)	S	S	P/PNNNN_N_NN/N_NN	M2	RL-free cure
O	15.2 (40)	3+; 3+	No	NA	R GFXMIC 2 (90Val)	S	S	P/PNN_N_N_NN/NNNN	M2	RL-free cure
P	19.2 (48)	3+; 2+	No	NA	R GFXMIC 1 (WT)	S	S	P/PPNNN_N_NN/NNNN	M3	RL-free cure
Q	16.6 (44)	1+; Sc	No	NA	R GFXMIC 8 (94Asn)	S	R	P/NNN_NN_PP	M1/FL	Failure
R	19.7 (45)	3+; 3+	No	NA	R GFXMIC 4 (91Pro)	S	S	P/PNNNN_N_NP	M2/FL	Failure
S	19.6 (52)	3+; 2+	No	NA	R GFXMIC 8 (94Gly)	S	S	P/PNNN_P_PP	M2/FL	Failure
T	11.6 (25)	3+; 2+	No	NA	R GFXMIC 2 (94Gly)	S	S	P/PP	None	Died
U	15.0 (38)	3+; 3+	No	NA	S	S	R	P/NNNN_N_N_N_/N_N	M1	RL-free cure
V	15.6 (42)	3+; 3+	No	NA	S	S	R	P/NNNN_N_NN_/NNNN	M1	RL-free cure

Drugs: B: bedaquiline; C: clofazimine; E: ethambutol; Et: ethionamide; G: gatifloxacin; Hh: high-dose isoniazid; L: linezolid; Lf: levofloxacin; K: kanamycin; O: ofloxacin; Pt: prothionamide; Z: pyrazinamide. Regimens: BDQ-STR: bedaquiline-based shorter treatment regimen (4BKPtHhCEZ/ 5BCEZ); LZD/GFX-STR: linezolid-based shorter treatment regimen (2LGKPtHhCEZ/ 2GKPtHhCEZ/ 5GCEZ); OFX-regimen: 4OKPtHCEZ/ 12OHCEZ; GFX-STR: 4GKPtHCEZ/ 5GCEZ; LFX-STR: 4LfKPtHCEZ/ 5LfCEZ. AR: auramine, BMI: body mass index, FDA: fluorescein diacetate vital staining; FL: failure; FQ: fluoroquinolone; gDST: genotypic drug susceptibility testing; GFXMIC: minimum inhibitory concentration for GFX; IQR: interquartile range; LTFU: lost to follow-up; NA: not applicable; pDST: phenotypic drug susceptibility testing; RL: relapse; SL: second-line TB treatment regimen; SSM: sputum-smear microscopy; R: resistant; S: susceptible; U: unknown; P: positive; N: negative; Sc: scanty; \_: unknown. <sup>#</sup>: switched during the first or second month of fluoroquinolone-based rifampicin-resistant tuberculosis treatment to the BDQ-STR (in one patient during a second STR, after treatment failure for a previous second-line treatment outcome). <sup>†</sup>: culture results are shown as follows: baseline result/results during 9–11 months of treatment/post-treatment results with 6-monthly sampling. In case no sputum sample was obtained, patients were assessed clinically. <sup>†</sup>: Chi-squared test or Fisher's exact test for categorical variables, to assess correlations between categorical variables and belonging to the BDQ-STR or LZD/GFX-cohort, not including the three patients excluded. Also observations with missing data were excluded. Kruskal–Wallis rank test for the continuous variable BMI. <sup>§</sup>: binary variable for outcome: relapse-free cure as favourable and failure, relapse or death as unfavourable outcome. <sup>f</sup>: no bedaquiline acquired resistance on genotypic DST. <sup>##</sup>: both cases: at baseline sputum smear microscopy positive on AR and FDA (thus showing viability), then conversion at M1. <sup>¶¶</sup>: conversion on AR and FDA at month 2.

Of 18 patients, five were previously unsuccessfully treated with a STR. All five were treated with the BDQ-STR. The vast majority of patients had a high bacillary load on smear microscopy. Of 17 with fluoroquinolone-resistant RR-TB, MIC data showed high-level resistance in 16 patients. One patient treated with the LZD/GFX-STR had low-level fluoroquinolone resistance.

Of seven patients treated with an LZD/GFX-STR, three (43%) were cured relapse-free. No patient had stable culture conversion from month 1, and 2 (29%) at month 2. Three patients experienced treatment failure. Another patient died after 2 months of treatment while culture and smears were still positive. This young woman started treatment in a very critical condition, with cavitory disease, a very high bacillary load and body mass index (BMI) of  $11.6 \text{ kg}\cdot\text{m}^{-2}$ , with severe vomiting.

Of 11 patients treated with a BDQ-STR, nine (82%) were cured relapse-free. Of 11, seven (64%) converted at month 1 and 9 (82%) at month 2. One patient first had culture conversion at month 3 and was cured, but experienced relapse 5 months after cure. A second patient first converted on smear microscopy at month 2 but then died before culture could be done. The cause of death was recorded as cardiorespiratory insufficiency. Both patients had advanced TB disease, with a very low BMI, respectively 12.2 and  $12.8 \text{ kg}\cdot\text{m}^{-2}$ , a high bacillary load, and converted relatively late.

Stable conversion occurred more rapidly in patients treated with a BDQ-STR (log-rank test:  $p=0.02$ ; time to conversion was the time between treatment start and the first negative culture that was not followed by a positive culture; in one patient without culture results, fluorescein diacetate vital staining [10] results were used). Stable culture conversion at 1 month occurred in seven of 11 patients on a BDQ-STR and in none of seven on an LZD/GFX-STR ( $p=0.01$ ). Relapse-free cure (*versus* failure, relapse or death) was more frequent in patients treated with the BDQ-STR (82% (9/11) *versus* 43% (3/7);  $p=0.09$ , Chi-squared test), but the difference was not significant at level 0.05.

Our study confirmed that bedaquiline can act as a core drug for the treatment of patients with fluoroquinolone-resistant RR-TB.

Previous use is being included as a criterium to evaluate the likely effectiveness of TB drugs [7]. Our results suggest this mainly holds for the drug exerting the highest killing activity, the core drug of the regimen. Indeed, in our study the same background regimen was effective when combined with another core drug. "Previously used" should not be considered an absolute criterium for excluding a companion drug with lower killing activity than other drugs in the regimen.

In the one patient with relapse, no resistance to bedaquiline was acquired on genotypic DST. Companion drugs are key to assure early resistance prevention. A study from Pakistan showed that second-line injectable drugs protected well against acquired bedaquiline resistance [11]. Bedaquiline-containing regimens without high resistance preventing activity result in a too high rate of acquired bedaquiline resistance [12].

In the LZD/GFX STR, gatifloxacin combined with linezolid during the early stage of treatment did not exert the same effect as bedaquiline in the GFX-STR. Despite the bactericidal activity of kanamycin in all patients treated with the LZD/GFX-STR and ethionamide in most, and the additional activity of linezolid, no patient on LZD/GFX-STR had early stable conversion at 1 month, while the majority on the BDQ-STR experienced early conversion. Probably there was little residual activity of gatifloxacin and linezolid does not seem to drive early culture conversion, which suggests that linezolid does not qualify as core drug. Without core drugs, regimens are less effective [8]. On the other hand, in Niger linezolid was effectively used as companion drug in patients with fluoroquinolone-susceptible RR-TB and a contraindication for treatment with second-line injectable drugs [13].

Our sample size was too small to conclude whether relapse-free cure was significantly higher with 95% certainty for the BDQ-STR compared to the LZD/GFX-STR. However, data on culture conversion showed that the BDQ-STR had an earlier killing effect than the LZD/GFX-STR in a cohort mainly consisting of patients with fluoroquinolone-resistant cohort.

In conclusion, bedaquiline acted as core drug in a third-line RR-TB treatment regimen in patients with presumptive fluoroquinolone resistance, including patients previously treated with second-line drugs. A second-line injectable drug provided the necessary high resistance preventing activity.

**Tom Decroo** <sup>1</sup>, **Kya Jai Maug Aung**<sup>2</sup>, **Mohamed Anwar Hossain**<sup>2</sup>, **Mourad Gumusboga**<sup>3</sup>, **Nimer Ortuno-Gutierrez**<sup>4</sup>, **Bouke Catherine De Jong** <sup>3</sup> and **Armand Van Deun**<sup>5</sup>

<sup>1</sup>Institute of Tropical Medicine, Unit of HIV and TB, Dept of Clinical Sciences, Antwerp, Belgium. <sup>2</sup>Damien Foundation Bangladesh, Dhaka, Bangladesh. <sup>3</sup>Institute of Tropical Medicine, Unit of Mycobacteriology, Dept of Biomedical Sciences, Antwerp, Belgium. <sup>4</sup>Damien Foundation, Brussels, Belgium. <sup>5</sup>Independent Consultant, Leuven, Belgium.

Corresponding author: Tom Decroo ([tdecroo@itg.be](mailto:tdecroo@itg.be))

Acknowledgements: We thank the clinic and laboratory staff of Damien Foundation Bangladesh as well as the staff of the mycobacteriology laboratory of the Institute of Tropical Medicine in Antwerp.

Author contributions: T. Decroo and A. Van Deun conceived the study. A. Van Deun, K.J.M. Aung, M.A. Hossain and M. Gumusboga collected and prepared the Damien Foundation Bangladesh data. M.A. Hossain and M. Gumusboga conducted drug susceptibility testing. T. Decroo and A. Van Deun analysed the data. All co-authors contributed to the interpretation of the findings. A. Van Deun and T. Decroo wrote the first draft. All co-authors critically revised the subsequent versions and approved the final version.

Conflicts of interest: B.C. De Jong reports grant funding from USAID for the STREAM trial on Bedaquiline for MDR-TB; and membership of a Panacea scientific advisory board, both within the 36 months prior to manuscript submission. All other authors declare no conflicts of interest.

## References

- 1 Aung KJM, Van Deun A, Declercq E, *et al.* Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc Lung Dis* 2014; 18: 1180–1187.
- 2 Van Deun A, Decroo T, Kuaban C, *et al.* Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB. *Int J Tuberc Lung Dis* 2019; 23: 965–971.
- 3 Decroo T, Aung KJM, Hossain MA, *et al.* Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimens outcomes. *PLoS ONE* 2020; 15: e0238016.
- 4 Koirala S, Borisov S, Danila E, *et al.* Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort. *Pulmonology* 2021; 27: 403–412.
- 5 Dickinson JM, Allen BW, Mitchison DA. Slide culture sensitivity tests. *Tubercle* 1989; 70: 115–121.
- 6 Van Deun A, Chiang CY. Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance. *Eur Respir J* 2017; 49: 1700223.
- 7 World Health Organization. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment. Geneva, World Health Organization, 2020.
- 8 Van Deun A, Decroo T, Piubello A, *et al.* Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. *Int J Tuberc Lung Dis* 2018; 22: 239–245.
- 9 Lempens P, Decroo T, Aung KJM, *et al.* Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. *Int J Infect Dis* 2020; 100: 357–365.
- 10 Van Deun A, Maug AKJ, Hossain A, *et al.* Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. *Int J Tuberc Lung Dis* 2012; 16: 1174–1179.
- 11 Tahseen S, Van Deun A, de Jong BC, *et al.* Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? *J Antimicrob Chemother* 2021; 76: 831–835.
- 12 Nimmo C, Millard J, Brien K, *et al.* Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. *Eur Respir J* 2020; 55: 1902383.
- 13 Souleymane MB, Piubello A, Lawan IM, *et al.* High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. *Eur Respir J* 2020; 57: 2002250.